Although the post-pandemic future is much in debate, bacterial infections are transforming into an urgent and ever growing threat to human health all over the world.
What can Switzerland add to?
Switzerland has been a global innovation hub for medtech, pharma and biotech – and is home to large pharmaceutical conglomerates like Novartis and Roche. Being a part of BMSV is a great opportunity to implement the promising potential for collaboration in AMR – an opportunity that we continue to pursue with our curated Indo-Swiss programs for a better tomorrow. Our tailored exchanges aim at revitalizing antibiotic discovery, for which we are bringing together Switzerland’s foremost scientists in the field of antimicrobial research. Through this, we aim to break silos within AMR research and accelerate the clinical development of new antimicrobial therapies to win the race against superbugs.
Watch this space for more.